Evidence map›Paper›PMID 40025532›Full record

ArticleCancer cell international2025

CENPF interaction with PLA2G4A promotes glioma growth by modulating mTORC1 and NF-κB pathways.

Junhong Li, Moxuan Zhang, Qiang Sun, Xinglan Li, Fei Du, Yanhao Cheng, Shuzhi Li, Jian Zhang

Abstract read
In one paragraph

Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Junhong Li *Linyi People's Hospital, Shandong Second Medical University, Linyi, Shandong Province, 276000, China.
Moxuan Zhang *Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China. mxzhang91@163.com.
Qiang SunDepartment of Neurosurgery, Linyi People's Hospital, Linyi, Shandong Province, 276000, China.
Xinglan LiLinyi People's Hospital, Shandong Second Medical University, Linyi, Shandong Province, 276000, China.
Fei DuDepartment of Neurosurgery, Linyi People's Hospital, Linyi, Shandong Province, 276000, China.
Yanhao ChengDepartment of Neurosurgery, Linyi People's Hospital, Linyi, Shandong Province, 276000, China.
Shuzhi LiDepartment of Neurosurgery, Gaomi Traditional Chinese Medicine Hospital, Weifang, Shandong Province, 261500, China. gmzyylsz@163.com.
Jian ZhangDepartment of Neurosurgery, Linyi People's Hospital, Linyi, Shandong Province, 276000, China. honest20699@126.com.

Funding

the Linyi Science and Technology Development Plan Project 202120064the Medical and Health Science and Technology Development Project of Shandong 202104040538
6 · The paper itself

Abstract

backgroundGlioma is the most common primary malignant tumor of the central nervous system, and due to the limited effectiveness of traditional single-target therapies, there is an urgent need for new therapeutic targets. Centromere protein F (CENPF) belongs to the centromere protein family and is mainly involved in the regulation of the cell cycle. CENPF has recently been found to play a key role in tumorigenesis and tumor progression, but its role in gliomas has not been well studied.

methodsThe expression level and clinical information of CENPF were obtained by analyzing the TCGA, CGGA and GEO databases. Immunohistochemistry and western blot analysis were used to quantitatively detect the expression of CENPF in glioma tissues and cell lines. Gene set enrichment analysis (GSEA) of TCGA and GSE16011 datasets was used to explore the molecular mechanism of the CENPF. CENPF-interacting proteins were detected by molecular docking and co-immunoprecipitation (Co-IP). After silencing CENPF, CCK-8 assay, Transwell assay and flow cytometry were used to detect changes in cell proliferation, invasion, cell cycle and apoptosis, and Western blot was used to detect changes in signaling pathway protein levels.

resultsBioinformatics analysis showed that CENPF was generally highly expressed in gliomas and was associated with poor prognosis. This result was confirmed in glioma samples from our hospital. Multivariate Cox regression analysis showed that CENPF was an independent prognostic marker for gliomas. Western blot analysis in vitro showed that CENPF was overexpressed in the U251 and LN229 cell lines; therefore, these two cell lines were selected for subsequent experiments. GSEA analysis showed that CENPF was mainly involved in the G2/M phase-mediated cell cycle and P53 signaling pathway. Flow cytometry analysis confirmed that silencing CENPF induced G2/M phase arrest and increased apoptosis in glioma cells. Subsequent experiments confirmed that CENPF influences the epithelial-mesenchymal transition (EMT) process through the mTORC1 signaling pathway. Molecular docking and Co-IP assay revealed that CENPF exerts its effects by interacting with PLA2G4A promoting the downstream signaling pathway. Finally, we found that silencing CENPF combined with a PLA2G4A inhibitor (AACOCF3) induced glioma cell apoptosis and exhibited anti-glioma effects.

conclusionsThis study found that CENPF plays a key role in promoting tumorigenesis through its interaction with PLA2G4A. This study provides a theoretical foundation for advancing multi-targeted therapies in glioma and for developing strategies to overcome tumor drug resistance.

Indexed as

Bioinformatics analysisCENPFGliomaPLA2G4ASignaling pathway

Identifiers

PMID40025532
PMCPMC11871623

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.